Connect Biopharma Announces Positive Preliminary Topline Data From Its Global Phase 2 Study Of Rademikibart As An Add-On Treatment For Acute Exacerbations In Adults With Copd And Type 2 Inflammation

Connect Biopharma Holdings Ltd NASDAQ:CNTB